Forum: Financial Investment Forum. - Discuss Stocks, Cryptocurrency, And Other Financial Investments

Thread: Read if you want one stock you can retire on

  1. #226  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,622


    Predictive Technology Group Accelerates Research Sample Collections to Support Development of Personalized Molecular Diagnostics and Clinical Therapies

    Subsidiary Predictive Laboratories hits milestone with 2,500 samples collected and processed since acquiring CLIA operations in March 2019; four new research sample collection initiatives set to begin this quarter

    Email Print Friendly Share
    August 20, 2019 09:15 ET | Source: Predictive Technology Group, Inc.


    SALT LAKE CITY, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories™ has collected over 2,500 DNA samples along with comprehensive medical records since acquiring its CLIA operations in March 2019. Predictive is broadening its research initiatives by acquiring new sample collections in chronic pain, pregnancy complications, autism, and both female and male infertility.
    Research is conducted following strict protocols approved by external Institutional Review Boards. Hundreds of individuals each month have voluntarily consented to share their medical histories and DNA samples for ongoing research. All research subjects are informed that their samples will be used in aggregate to develop new commercial diagnostic and therapeutic products. To ensure privacy, research samples and datasets are deidentified and securely stored.
    Personalized medicine and the development of new therapeutics are expected to play a critical role in human health. Access to high-quality biospecimens from Predictive’s biobank will be crucial for furthering the Company’s biomedical and translational research, and ultimately its development of personalized molecular diagnostics and clinical therapies. Current sample collection efforts are designed to strategically augment Predictive’s existing library of over 300,000 DNA samples that the Company believes will produce valuable insights into future research and development projects.
    The development of effective diagnostic and treatment products requires identification of genetic markers that are useful for early detection, prevention, and personalized treatment of specific medical conditions. Genetic discoveries lead to insights into the cause and progression of disease and often suggest novel means of treating serious chronic conditions. Modern genetic research requires large numbers of well-characterized samples; one set for discovery, another independent set for replication, a third for validation, and a fourth to prove the clinical utility.
    “The ability to discover specific genetic markers related to the diagnosis, prognosis, and therapeutic response for disease targets can help Predictive find solutions that could transform medical care,” said Bradley Robinson, CEO of Predictive Technology Group. “A crucial requirement for personalized medicine is the availability of an extensive collection of both human diseased and healthy samples with well-documented medical records.
    “Through investment in our biobank initiatives and collaboration with others who have relevant research collections, we reached this new collection milestone of 2,500 samples very rapidly and we continue to build on our database,” he added. “At Predictive Laboratories, we have state-of-the-art capabilities for automated DNA extraction, sample handling, and high-throughput genotyping and sequencing that support our planned development of breakthrough diagnostics and therapeutics.”
    About Predictive Laboratories, Inc.
    Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide™, to selected collaborators. ARTguide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
    Forward-Looking Statements
    To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
    Contacts:
    For more information, visit www.predtechgroup.com or contact Investor Relations:
    Investor Contact
    LHA Investor Relations
    Jody Cain jcain@lhai.com
    Kevin Mc Cabe kmccabe@lhai.com
    310-691-7100

    Reply With Quote  
     

  2. #227  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,622


    Predictive Technology Group Names Biologic Industry Leader Jeff Acuff As Chief Commercial Officer Of Predictive Biotech

    Email Print Friendly Share
    August 23, 2019 09:15 ET | Source: Predictive Technology Group, Inc.


    SALT LAKE CITY, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces the appointment of Jeff Acuff to the newly created position of Chief Commercial Officer of its wholly owned subsidiary Predictive Biotech.
    Mr. Acuff will be responsible for the commercial strategy of Predictive Biotech’s existing human cell and tissue product (HCT/P) business, and will implement programs and business development strategies aimed at driving sales and increasing physician awareness of HCT/P treatment options. He also will lead the commercial development of new product candidates, and the expansion and use of the human cell and tissue products into new vertical-market targets that include wound management and aesthetics. Additionally, he will oversee the long-term business development strategy for cellular therapies being developed by Predictive Therapeutics.
    “Jeff brings a deep knowledge of the healthcare industry, a clear focus of physician and patient needs, and a proven track record of successful execution in ortho-biologic sales, which makes him ideally suited to lead the commercial efforts for Predictive Biotech, as well as the development of the Company’s sales expansion plans,” said Mr. Eric Olson, CEO of Predictive Biotech. “Under his leadership, I am confident we will continue to build upon the Company's solid foundation in sales and strengthen our ability to bring quality products to our physician customers.”
    "I am very excited and honored to lead such a talented and proven team as we continue to focus on building the Company’s portfolio and capabilities for the future,” said Mr. Acuff. “Predictive Biotech has made the safety, efficacy and quality of its human cell and tissue products the number one priority in serving physician customers and their patients. The Company has delivered over 95,000 allografts to date and is proud to serve as a reliable, quality manufacturer. I look forward to building upon these trusted customer relationships to best serve patient needs.”
    Mr. Acuff has more than 25 years of commercial and leadership experience concentrated in the medical device and biologics industry, and has a proven track record for building high-performing teams and achieving exceptional results. He most recently served as the Commercial Excellence Leader for GE Healthcare. Prior to joining GE Healthcare, Mr. Acuff was Senior Vice President of Sales leading the commercial efforts of Bioventus, a private equity-owned ortho-biologics company, and was Vice President of Sales, Americas for Varian Medical Systems, where he helped develop and lead the commercial strategy and implementation for its radiation oncology business. Before that, he served for 13 years at Medtronic in various roles, including Vice President of Sales, Biologics and Vice President of Enabling Technologies Sales & Marketing. During his tenure at Medtronic, he led sales organizations in both mature and fast-growing market segments including interventional cardiology, interventional radiology, endovascular surgery, spine, and biologics.
    Mr. Acuff holds a Bachelor of Business Administration in Management from the University of Memphis and completed an Executive Program at the Kellogg School of Management at Northwestern University.
    About Predictive Biotech, Inc.
    Predictive Biotech, Inc., a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
    Forward-Looking Statements
    To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
    Contacts:
    For more information, visit www.predtechgroup.com or contact Investor Relations:
    Investor Contact
    LHA Investor Relations
    Jody Cain jcain@lhai.com
    Kevin Mc Cabe kmccabe@lhai.com
    310-691-7100

    Reply With Quote  
     

  3. #228  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,622
    Predictive Launches PGxPLUS+ Test for Patients with Chronic Pain of Endometriosis and Other Illnesses


    AUGUST 20, 2019 BY JOANA CARVALHO, MSC
    IN NEWS.



    https://endometriosisnews.com/2019/08/20/predictive-launches-pgxplus-test-for-patients-with-chronic-pain/
    Reply With Quote  
     

  4. #229  
    RX Local MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    15,033
    Getting juicier by the day around here.
    Reply With Quote  
     

  5. #230  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,622
    Reply With Quote  
     

Posting Permissions
  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •